ABBV-383, a BCMA-CD3 bispecific antibody, in relapsed/refractory multiple myeloma: a multicenter, phase 1b dose optimization study with step-up dosing

被引：0

作者：

Baljevic, Muhamed ^{[1
]}

Magen, Hila ^{[2
,3
]}

Searle, Emma ^{[4
,5
]}

Jin, Ziyi ^{[6
]}

Strange, Elise ^{[6
]}

Svensson, Anders ^{[6
]}

Kumar, Shaji ^{[7
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[2] Chaim Sheba Med Ctr, Ramat Gan, Israel

[3] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[4] Christie Hosp NHS Fdn Trust, Manchester, England

[5] Univ Manchester, Manchester, England

[6] AbbVie Inc, N Chicago, IL USA

[7] Mayo Clin, Rochester, MN USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-231

引用

页码：S162 / S163

页数：2

共 50 条

[21] A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Plesner, Torben
Harrison, Simon J.
Quach, Hang
Lee, Cindy H.
Bryant, Adam
Vangsted, Annette Juul
Estell, Jane
Delforge, Michel
Offner, Fritz
Twomey, Patrick
Choeurng, Voleak
Li, Junyi
Hendricks, Robert
Sumiyoshi, Teiko
Miller, Karen
Choi, Eunpi
Schjesvold, Fredrik H.
BLOOD, 2021, 138
[22] Trial in progress: linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma
Rodriguez-Otero, Paula
Joseph, Nisha
Kumar, Shaji
Leleu, Xavier
Manier, Salomon
Dimopoulos, Meletios
Mateos, Maria-Victoria
Oriol, Albert
Bumma, Naresh
Gong, Weiying
Roy, Pourab
Lorenc, Karen Rodriguez
Kroog, Glenn
Sarkaria, Shawn
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S60 - S60
[23] Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
Plesner T.
Harrison S.J.
Quach H.
Lee C.
Bryant A.
Vangsted A.
Estell J.
Delforge M.
Offner F.
Twomey P.
Choeurng V.
Li J.
Hendricks R.
Ruppert S.M.
Sumiyoshi T.
Miller K.
Cho E.
Schjesvold F.
Clinical Hematology International, 2023, 5 (1) : 43 - 51
[24] SUBCUTANEOUS DARATUMUMAB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO)
Mateos, M., V
Chari, A.
Nah, H.
Lokhorst, H.
Kaufman, J. L.
Moreau, P.
Oriol, A.
Plesner, T.
Benboubker, L.
Hellemans, P.
Masterson, T.
Clemens, P. L.
Liu, K.
San-Miguel, J.
Usmani, S. Z.
HAEMATOLOGICA, 2018, 103 : 32 - 33
[25] Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/ Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study
Mohty, Mohamad
Tomasson, Michael H.
Arnulf, Bertrand
Bahlis, Nizar J.
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Jethava, Yogesh
Gabayan, Afshin E.
Stevens, Don A.
Nooka, Ajay K.
Raje, Noopur
Iida, Shinsuke
Leip, Eric
Conte, Umberto
Czibere, Akos
Viqueira, Andrea
Lesokhin, Alexander M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S493 - S494
[26] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study
Raab, M. S.
Haenel, M.
Mohty, M.
Tomasson, M. H.
Arnulf, B.
Bahlis, N. J.
Prince, H. M.
Niesvizky, R.
Rodriguez-Otero, P.
Martinez-Lopez, J.
Koehne, G.
Jethava, Y.
Gabayan, A. E.
Stevens, D. A.
Nooka, A. K.
Raje, N.
Iida, S.
Leip, E.
Conte, U.
Czibere, A.
Viqueira, A.
Lesokhin, A. M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 177 - 178
[27] Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma
Martin, Thomas G.
Shah, Nina
Richter, Joshua
Vesole, David H.
Wong, Sandy W.
Huang, Chiung-Yu
Madduri, Deepu
Jagannath, Sundar
Siegel, David S.
Biran, Noa
Wolf, Jeffrey L.
Parekh, Samir
Cho, Hearn J.
Munster, Pamela
Richard, Shambavi
Ziti-Ljajic, Samira
Chari, Ajai
CANCER, 2021, 127 (11) : 1816 - 1826
[28] Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels W. C. J.
Moreau, Philippe
Garfall, Alfred L.
Bhutani, Manisha
Oriol, Albert
Nooka, Ajay K.
Martin, Thomas G.
Rosinol, Laura
Mateos, Maria-Victoria
Bahlis, Nizar
Popat, Rakesh
Besemer, Britta
Martinez Lopez, Joaquin
Krishnan, Amrita
Delforge, Michel
Trancucci, Danielle
Verona, Raluca I.
Stephenson, Tara
Chastain, Katherine
Sidana, Surbhi
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S25 - S26
[29] Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
Bahlis, Nizar J.
Raje, Noopur S.
Costello, Caitlin
Dholaria, Bhagirathbhai R.
Solh, Melhem M.
Levy, Moshe Y.
Tomasson, Michael H.
Dube, Harman
Liu, Feng
Liao, Kai Hsin
Basu, Cynthia
Skoura, Athanasia
Chan, Edward Michael
Trudel, Suzanne
Jakubowiak, Andrzej J.
Chu, Michael P.
Gasparetto, Cristina
Dalovisio, Andrew
Sebag, Michael
Lesokhin, Alexander M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[30] Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1
Cortes-Selva, Diana
Casneuf, Tineke
Vishwamitra, Deeksha
Stein, Sarah
Perova, Tatiana
Skerget, Sheri
Ramos, Elena
van Steenbergen, Laure
De Maeyer, Dries
Boominathan, Rengasamy
Lau, Onsay
Davis, Cuc
Banerjee, Arnob
Stephenson, Tara
Uhlar, Clarissa M.
Kobos, Rachel
Goldberg, Jenna D.
Pei, Lixia
Trancucci, Danielle
Girgis, Suzette
Lin, Shun Xin Wang
Wu, Liviawati S.
Moreau, Philippe
Usmani, Saad
Bahlis, Nizar Jacques
Van de Donk, Niels W. C. J.
Verona, Raluca
BLOOD, 2022, 140

← 1 2 3 4 5 →